Bavar­i­an Nordic ex­pands mon­key­pox vac­cine deal with US and up­dates '22 sales fig­ures — again

On the back of an ex­pand­ed mon­key­pox vac­cine deal with the US, Bavar­i­an Nordic is boost­ing its 2022 sales fore­cast — for the third time in the last month.

BAR­DA has or­dered an ad­di­tion­al 500,000 liq­uid-frozen dos­es of the Dan­ish com­pa­ny’s vac­cine Jyn­neos, which cov­ers both small­pox and mon­key­pox, for de­liv­ery this year. Along­side a pre­vi­ous or­der for 1.4 mil­lion dos­es placed back in 2020, this brings the US in­ven­to­ry to near­ly 2 mil­lion dos­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER